Borghaei et al. included 82 EGFR mutation NSCLC patients who progressed on EGFR-TKIs or platinum-containing regimens, and nivolumab did not significantly prolong PFS [25]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.